Close Menu

NEW YORK — Evotec and Indivumed said on Thursday that they have formed a new drug-discovery and -development alliance focused on non-small cell lung cancer.

Under the deal, the companies will use Evotec's bioinformatics analysis platform and drug discovery technologies with Indivumed's IndivuType database, which integrates patients' clinical information with genomic, transcriptomic, proteomic, and digital histopathology data derived from biospecimens.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.